Advertisement

Malignant Mesothelioma

  • Claire W. Michael
Chapter

Abstract

Malignant mesothelioma is a rare malignant lung tumor with a very poor prognosis. A malignant effusion is frequently the first clinical symptom of the disease, and a definitive diagnosis can spare the patient further diagnostic procedures with the risk of spreading along the biopsy site. A large percentage of these effusions are highly cellular, particularly those with the epithelioid variant. Recently, the International Mesothelioma Interest Group (IMIG) acknowledged cytology as an acceptable diagnostic method, and supplemental guidelines for the diagnosis of mesothelioma by cytology were published. This chapter reviewed the epidemiology, the clinical presentation, and the morphologic features diagnostic of mesothelioma with its various patterns. The differential diagnoses and diagnostic pitfalls, particularly reactive mesothelial proliferations, are discussed in detail, along with the role of up-to-date immunohistochemistry in establishing a definitive diagnosis.

References

  1. 1.
    Ismail-Khan R, Robinson LA, Williams CC Jr, Garrett CR, Bepler G, Simon GR. Malignant pleural mesothelioma: a comprehensive review. Cancer Control. 2006;13(4):255–63.PubMedCrossRefGoogle Scholar
  2. 2.
    Husain AN, Colby TV, Ordonez NG, et al. Guidelines for pathologic diagnosis of malignant mesothelioma: a consensus statement from the International Mesothelioma Interest Group. Arch Pathol Lab Med. Aug 2009;133(8):1317–31.PubMedGoogle Scholar
  3. 3.
    Hjerpe A, Ascoli V, Bedrossian CW, et al. Guidelines for the cytopathologic diagnosis of epithelioid and mixed-type malignant mesothelioma. Complementary statement from the International Mesothelioma Interest Group, also endorsed by the International Academy of Cytology and the Papanicolaou Society of Cytopathology. Acta Cytol. 2015;59(1):2–16.PubMedCrossRefGoogle Scholar
  4. 4.
    Husain AN, Colby T, Ordonez N, et al. Guidelines for pathologic diagnosis of malignant mesothelioma: 2012 update of the consensus statement from the International Mesothelioma Interest Group. Arch Pathol Lab Med. 2013;137(5):647–67.PubMedCrossRefGoogle Scholar
  5. 5.
    British Thoracic Society Standards of Care C. BTS statement on malignant mesothelioma in the UK, 2007. Thorax. 2007;62(Suppl 2):ii1–ii19.Google Scholar
  6. 6.
    van Zandwijk N, Clarke C, Henderson D, et al. Guidelines for the diagnosis and treatment of malignant pleural mesothelioma. J Thorac Dis. 2013;5(6):E254–307.PubMedPubMedCentralGoogle Scholar
  7. 7.
    Bedrossian CW. Asbestos-related diseases: a historical and mineralogic perspective. Semin Diagn Pathol. 1992;9(2):91–6.PubMedGoogle Scholar
  8. 8.
    Roggli VL, McGavran MH, Subach J, Sybers HD, Greenberg SD. Pulmonary asbestos body counts and electron probe analysis of asbestos body cores in patients with mesothelioma: a study of 25 cases. Cancer. 1982;50(11):2423–32.PubMedCrossRefGoogle Scholar
  9. 9.
    Mark EJ, Kradin RL. Pathological recognition of diffuse malignant mesothelioma of the pleura: the significance of the historical perspective as regards this signal tumor. Semin Diagn Pathol. 2006;23(1):25–34.PubMedCrossRefGoogle Scholar
  10. 10.
    Dogan AU, Dogan M, Hoskins JA. Erionite series minerals: mineralogical and carcinogenic properties. Environ Geochem Health. 2008;30(4):367–81.PubMedCrossRefGoogle Scholar
  11. 11.
    Boylan AM. Mesothelioma: new concepts in diagnosis and management. Curr Opin Pulm Med. 2000;6(2):157–63.PubMedCrossRefGoogle Scholar
  12. 12.
    Corson JM. Pathology of diffuse malignant pleural mesothelioma. Semin Thorac Cardiovasc Surg. Oct 1997;9(4):347–55.PubMedGoogle Scholar
  13. 13.
    Chirieac LR, Corson JM. Pathologic evaluation of malignant pleural mesothelioma. Semin Thorac Cardiovasc Surg. 2009;21(2):121–4.PubMedCrossRefGoogle Scholar
  14. 14.
    Alexander HR Jr. Surgical treatment of malignant peritoneal mesothelioma: past, present, and future. Ann Surg Oncol. 2010;17(1):21–2.PubMedCrossRefGoogle Scholar
  15. 15.
    Kerrigan SA, Turnnir RT, Clement PB, Young RH, Churg A. Diffuse malignant epithelial mesotheliomas of the peritoneum in women: a clinicopathologic study of 25 patients. Cancer. 2002;94(2):378–85.PubMedCrossRefGoogle Scholar
  16. 16.
    Hassan R, Remaley AT, Sampson ML, et al. Detection and quantitation of serum mesothelin, a tumor marker for patients with mesothelioma and ovarian cancer. Clin Cancer Res. 2006;12(2):447–53.PubMedCrossRefGoogle Scholar
  17. 17.
    Antman KH, Osteen RT, Klegar KL, et al. Early peritoneal mesothelioma: a treatable malignancy. Lancet. 1985;2(8462):977–81.PubMedCrossRefGoogle Scholar
  18. 18.
    Baratti D, Kusamura S, Cabras AD, Laterza B, Balestra MR, Deraco M. Lymph node metastases in diffuse malignant peritoneal mesothelioma. Ann Surg Oncol. 2010;17(1):45–53.PubMedCrossRefGoogle Scholar
  19. 19.
    Henderson DW. Malignant mesothelioma. New York: Hemisphere Publishing Corporation; 1992.Google Scholar
  20. 20.
    Matsuo T, Ito H, Anami M, Ikeda T, Nishihata S. Malignant peritoneal mesothelioma with squamous metaplasia. Cytopathology. 1993;4(6):373–8.PubMedCrossRefGoogle Scholar
  21. 21.
    Mayall FG, Gibbs AR. The histology and immunohistochemistry of small cell mesothelioma. Histopathology. 1992;20(1):47–51.PubMedCrossRefGoogle Scholar
  22. 22.
    Ordonez NG. Mesothelioma with clear cell features: an ultrastructural and immunohistochemical study of 20 cases. Hum Pathol. 2005;36(5):465–73.PubMedCrossRefGoogle Scholar
  23. 23.
    Chang HT, Yantiss RK, Nielsen GP, McKee GT, Mark EJ. Lipid-rich diffuse malignant mesothelioma: a case report. Hum Pathol. 2000;31(7):876–9.PubMedCrossRefGoogle Scholar
  24. 24.
    Klebe S, Mahar A, Henderson DW, Roggli VL. Malignant mesothelioma with heterologous elements: clinicopathological correlation of 27 cases and literature review. Modern Pathol. 2008;21(9):1084–94.CrossRefGoogle Scholar
  25. 25.
    Wilson GE, Hasleton PS, Chatterjee AK. Desmoplastic malignant mesothelioma: a review of 17 cases. J Clin Pathol. Apr 1992;45(4):295–8.PubMedPubMedCentralCrossRefGoogle Scholar
  26. 26.
    Ishikawa R, Kikuchi E, Jin M, et al. Desmoplastic malignant mesothelioma of the pleura: autopsy reveals asbestos exposure. Pathol Int. 2003;53(6):401–6.PubMedCrossRefGoogle Scholar
  27. 27.
    Yao DX, Shia J, Erlandson RA, Klimstra DS. Lymphohistiocytoid mesothelioma: a clinical, immunohistochemical and ultrastructural study of four cases and literature review. Ultrastruct Pathol. 2004;28(4):213–28.PubMedCrossRefGoogle Scholar
  28. 28.
    Henderson DW, Attwood HD, Constance TJ, Shilkin KB, Steele RH. Lymphohistiocytoid mesothelioma: a rare lymphomatoid variant of predominantly sarcomatoid mesothelioma. Ultrastruct Pathol. 1988;12(4):367–84.PubMedCrossRefGoogle Scholar
  29. 29.
    Shia J, Erlandson RA, Klimstra DS. Deciduoid mesothelioma: a report of 5 cases and literature review. Ultrastruct Pathol. 2002;26(6):355–63.PubMedCrossRefGoogle Scholar
  30. 30.
    Shanks JH, Harris M, Banerjee SS, et al. Mesotheliomas with deciduoid morphology: a morphologic spectrum and a variant not confined to young females. Am J Surg Pathol. 2000;24(2):285–94.PubMedCrossRefGoogle Scholar
  31. 31.
    Ordonez NG. Epithelial mesothelioma with deciduoid features: report of four cases. Am J Surg Pathol. 2000;24(6):816–23.PubMedCrossRefGoogle Scholar
  32. 32.
    Azzopardi JG. Oat-cell carcinoma of the bronchus. J Pathol Bacteriol. 1959;78:513–9.PubMedCrossRefGoogle Scholar
  33. 33.
    Talerman A, Montero JR, Chilcote RR, Okagaki T. Diffuse malignant peritoneal mesothelioma in a 13-year-old girl. Report of a case and review of the literature. Am J Surg Pathol. 1985;9(1):73–80.PubMedCrossRefGoogle Scholar
  34. 34.
    Henley JD, Loehrer PJ Sr, Ulbright TM. Deciduoid mesothelioma of the pleura after radiation therapy for Hodgkin's disease presenting as a mediastinal mass. Am J Surg Pathol. 2001;25(4):547–8.PubMedCrossRefGoogle Scholar
  35. 35.
    Serio G, Scattone A, Pennella A, et al. Malignant deciduoid mesothelioma of the pleura: report of two cases with long survival. Histopathology. 2002;40(4):348–52.PubMedCrossRefGoogle Scholar
  36. 36.
    Paintal A. The evolving role of effusion cytology in the diagnosis of malignant mesothelioma. Cytopathology. 2015;26(3):137–8.PubMedCrossRefGoogle Scholar
  37. 37.
    Renshaw AA, Dean BR, Antman KH, Sugarbaker DJ, Cibas ES. The role of cytologic evaluation of pleural fluid in the diagnosis of malignant mesothelioma. Chest. 1997;111(1):106–9.PubMedCrossRefGoogle Scholar
  38. 38.
    Nguyen GK. Cytopathology of pleural mesotheliomas. Am J Clin Pathol. 2000;114(Suppl):S68–81.PubMedGoogle Scholar
  39. 39.
    Fetsch PA, Abati A. Immunocytochemistry in effusion cytology: a contemporary review. Cancer. 2001;93(5):293–308.PubMedCrossRefGoogle Scholar
  40. 40.
    Westfall DE, Fan X, Marchevsky AM. Evidence-based guidelines to optimize the selection of antibody panels in cytopathology: pleural effusions with malignant epithelioid cells. Diagn Cytopathol. 2010;38(1):9–14.PubMedGoogle Scholar
  41. 41.
    Rakha EA, Patil S, Abdulla K, Abdulkader M, Chaudry Z, Soomro IN. The sensitivity of cytologic evaluation of pleural fluid in the diagnosis of malignant mesothelioma. Diagn Cytopathol. 2010;38(12):874–9.PubMedCrossRefGoogle Scholar
  42. 42.
    Tao LC. The cytopathology of mesothelioma. Acta Cytol. 1979;23(3):209–13.PubMedGoogle Scholar
  43. 43.
    Hasegawa S, Kondo N, Matsumoto S, et al. Practical approaches to diagnose and treat for T0 malignant pleural mesothelioma: a proposal for diagnostic total parietal pleurectomy. Int J Clin Oncol. 2012;17(1):33–9.PubMedCrossRefGoogle Scholar
  44. 44.
    Bedrossian CWM. The cytologic diagnosis of malignant mesothelioma. In: Michael CW, Bedrossian CWM, editors. Cytohistology of small tissue samples. Cambridge, UK Kingdom: Cambridge University Press; 2015.Google Scholar
  45. 45.
    Papanicolaou G. Atlas of exfoliative cytology. Cambridge, MA: harvard University Press; 1956.Google Scholar
  46. 46.
    Naylor B. The exfoliative cytology of diffuse malignant mesothelioma. J Pathol Bacteriol. 1963;86:293–8.PubMedCrossRefGoogle Scholar
  47. 47.
    Roberts GH, Campbell GM. Exfoliative cytology of diffuse mesothelioma. J Clin Pathol. 1972;25(7):577–82.PubMedPubMedCentralCrossRefGoogle Scholar
  48. 48.
    Whitaker D, Shilkin KB. The cytology of malignant mesothelioma in Western Australia. Acta Cytol. 1978;22(2):67–70.PubMedGoogle Scholar
  49. 49.
    Ehya H. The cytologic diagnosis of mesothelioma. Semin Diagn Pathol. 1986;3(3):196–203.PubMedGoogle Scholar
  50. 50.
    Bedrossian CW, Bonsib S, Moran C. Differential diagnosis between mesothelioma and adenocarcinoma: a multimodal approach based on ultrastructure and immunocytochemistry. Semin Diagn Pathol. 1992;9(2):124–40.PubMedGoogle Scholar
  51. 51.
    Kho-Duffin J, Tao LC, Cramer H, Catellier MJ, Irons D, Ng P. Cytologic diagnosis of malignant mesothelioma, with particular emphasis on the epithelial noncohesive cell type. Diagn Cytopathol. 1999;20(2):57–62.PubMedCrossRefGoogle Scholar
  52. 52.
    Patel NP, Taylor CA, Levine EA, Trupiano JK, Geisinger KR. Cytomorphologic features of primary peritoneal mesothelioma in effusion, washing, and fine-needle aspiration biopsy specimens: examination of 49 cases at one institution, including post-intraperitoneal hyperthermic chemotherapy findings. Am J Clin Pathol. 2007;128(3):414–22.PubMedCrossRefGoogle Scholar
  53. 53.
    Whitaker D. Cell aggregates in malignant mesothelioma. Acta Cytol. 1977;21(2):236–9.PubMedGoogle Scholar
  54. 54.
    Gillespie FR, van der Walt JD, Derias N, Kenney A. Deciduoid peritoneal mesothelioma. A report of the cytological appearances. Cytopathology. 2001;12(1):57–61.PubMedCrossRefGoogle Scholar
  55. 55.
    Huang CC, Michael CW. Deciduoid mesothelioma: cytologic presentation and diagnostic pitfalls. Diagn Cytopathol. 2013;41(7):629–35.PubMedCrossRefGoogle Scholar
  56. 56.
    Ustun H, Astarci HM, Sungu N, Ozdemir A, Ekinci C. Primary malignant deciduoid peritoneal mesothelioma: a report of the cytohistological and immunohistochemical appearances. Diagn Cytopathol. 2011;39(6):402–8.PubMedCrossRefGoogle Scholar
  57. 57.
    Reis-Filho JS, Pope LZ, Milanezi F, Balderrama CM, Serapiao MJ, Schmitt FC. Primary epithelial malignant mesothelioma of the pericardium with deciduoid features: cytohistologic and immunohistochemical study. Diagn Cytopathol. 2002;26(2):117–22.PubMedCrossRefGoogle Scholar
  58. 58.
    Ikeda K, Suzuki T, Tate G, Mitsuya T. Cytomorphologic features of well-differentiated papillary mesothelioma in peritoneal effusion: a case report. Diagn Cytopathol. 2008;36(7):512–5.PubMedCrossRefGoogle Scholar
  59. 59.
    Hejmadi R, Ganesan R, Kamal NG. Malignant transformation of a well-differentiated peritoneal papillary mesothelioma. Acta Cytol. 2003;47(3):517–8.PubMedGoogle Scholar
  60. 60.
    Cook DS, Attanoos RL, Jalloh SS, Gibbs AR. ‘Mucin-positive’ epithelial mesothelioma of the peritoneum: an unusual diagnostic pitfall. Histopathology. 2000;37(1):33–6.PubMedCrossRefGoogle Scholar
  61. 61.
    Triol JH, Conston AS, Chandler SV. Malignant mesothelioma. Cytopathology of 75 cases seen in a New Jersey community hospital. Acta Cytol. 1984;28(1):37–45.PubMedGoogle Scholar
  62. 62.
    Whitaker D, Shilkin KB. Diagnosis of pleural malignant mesothelioma in life—a practical approach. J Pathol. 1984;143(3):147–75.PubMedCrossRefGoogle Scholar
  63. 63.
    Welker L, Muller M, Holz O, Vollmer E, Magnussen H, Jorres RA. Cytological diagnosis of malignant mesothelioma—improvement by additional analysis of hyaluronic acid in pleural effusions. Virch Arch. 2007;450(4):455–61.CrossRefGoogle Scholar
  64. 64.
    Ordonez NG. Application of immunohistochemistry in the diagnosis of epithelioid mesothelioma: a review and update. Hum Pathol. 2013;44(1):1–19.PubMedCrossRefGoogle Scholar
  65. 65.
    Beasley MB. Immunohistochemistry of pulmonary and pleural neoplasia. Arch Pathol Lab Med. 2008;132(7):1062–72.PubMedGoogle Scholar
  66. 66.
    Ordonez NG. What are the current best immunohistochemical markers for the diagnosis of epithelioid mesothelioma? A review and update. Hum Pathol. 2007;38(1):1–16.PubMedCrossRefGoogle Scholar
  67. 67.
    Pu RT, Pang Y, Michael CW. Utility of WT-1, p63, MOC31, mesothelin, and cytokeratin (K903 and CK5/6) immunostains in differentiating adenocarcinoma, squamous cell carcinoma, and malignant mesothelioma in effusions. Diagn Cytopathol. 2008;36(1):20–5.PubMedCrossRefGoogle Scholar
  68. 68.
    Hanna A, Pang Y, Bedrossian CW, Dejmek A, Michael CW. Podoplanin is a useful marker for identifying mesothelioma in malignant effusions. Diagn Cytopathol. 2010;38(4):264–9.PubMedGoogle Scholar
  69. 69.
    Saad RS, Cho P, Liu YL, Silverman JF. The value of epithelial membrane antigen expression in separating benign mesothelial proliferation from malignant mesothelioma: a comparative study. Diagn Cytopathol. 2005;32(3):156–9.PubMedCrossRefGoogle Scholar
  70. 70.
    Bassarova AV, Nesland JM, Davidson B. D2-40 is not a specific marker for cells of mesothelial origin in serous effusions. Am J Surg Pathol. 2006;30(7):878–82.PubMedCrossRefGoogle Scholar
  71. 71.
    Ascoli V, Scalzo CC, Taccogna S, Nardi F. The diagnostic value of thrombomodulin immunolocalization in serous effusions. Arch Pathol Lab Med. 1995;119(12):1136–40.PubMedGoogle Scholar
  72. 72.
    Fetsch PA, Abati A, Hijazi YM. Utility of the antibodies CA 19-9, HBME-1, and thrombomodulin in the diagnosis of malignant mesothelioma and adenocarcinoma in cytology. Cancer. 1998;84(2):101–8.PubMedCrossRefGoogle Scholar
  73. 73.
    Mimura T, Ito A, Sakuma T, et al. Novel marker D2-40, combined with calretinin, CEA, and TTF-1: an optimal set of immunodiagnostic markers for pleural mesothelioma. Cancer. 2007;109(5):933–8.PubMedCrossRefGoogle Scholar
  74. 74.
    Lozano MD, Panizo A, Toledo GR, Sola JJ, Pardo-Mindan J. Immunocytochemistry in the differential diagnosis of serous effusions: a comparative evaluation of eight monoclonal antibodies in Papanicolaou stained smears. Cancer. 2001;93(1):68–72.PubMedCrossRefGoogle Scholar
  75. 75.
    Jo VY, Cibas ES, Pinkus GS. Claudin-4 immunohistochemistry is highly effective in distinguishing adenocarcinoma from malignant mesothelioma in effusion cytology. Cancer Cytopathol. 2014;122(4):299–306.PubMedCrossRefGoogle Scholar
  76. 76.
    Wiseman W, Michael CW, Roh MH. Diagnostic utility of PAX8 and PAX2 immunohistochemistry in the identification of metastatic Mullerian carcinoma in effusions. Diagn Cytopathol. 2011;39(9):651–6.PubMedCrossRefGoogle Scholar
  77. 77.
    Davidson B, Stavnes HT, Hellesylt E, et al. MMP-7 is a highly specific negative marker for benign and malignant mesothelial cells in serous effusions. Hum Pathol. 2016;47(1):104–8.PubMedCrossRefGoogle Scholar
  78. 78.
    Sack MJ, Roberts SA. Cytokeratins 20 and 7 in the differential diagnosis of metastatic carcinoma in cytologic specimens. Diagn Cytopathol. 1997;16(2):132–6.PubMedCrossRefGoogle Scholar
  79. 79.
    Ordonez NG. The diagnostic utility of immunohistochemistry in distinguishing between epithelioid mesotheliomas and squamous carcinomas of the lung: a comparative study. Modern Pathol. 2006;19(3):417–28.CrossRefGoogle Scholar
  80. 80.
    Hwang HC, Sheffield BS, Rodriguez S, et al. Utility of BAP1 immunohistochemistry and p16 (CDKN2A) FISH in the diagnosis of malignant mesothelioma in effusion cytology specimens. Am J Surg Pathol. 2016;40(1):120–6.PubMedCrossRefGoogle Scholar
  81. 81.
    Cigognetti M, Lonardi S, Fisogni S, et al. BAP1 (BRCA1-associated protein 1) is a highly specific marker for differentiating mesothelioma from reactive mesothelial proliferations. Modern Pathol. 2015;28(8):1043–57.CrossRefGoogle Scholar
  82. 82.
    Andrici J, Sheen A, Sioson L, et al. Loss of expression of BAP1 is a useful adjunct, which strongly supports the diagnosis of mesothelioma in effusion cytology. Modern Pathol. 2015;28(10):1360–8.CrossRefGoogle Scholar
  83. 83.
    Hasteh F, Lin GY, Weidner N, Michael CW. The use of immunohistochemistry to distinguish reactive mesothelial cells from malignant mesothelioma in cytologic effusions. Cancer Cytopathol. 2010;118(2):90–6.PubMedCrossRefGoogle Scholar
  84. 84.
    Sivertsen S, Berner A, Michael CW, Bedrossian C, Davidson B. Cadherin expression in ovarian carcinoma and malignant mesothelioma cell effusions. Acta Cytol. 2006;50(6):603–7.PubMedCrossRefGoogle Scholar
  85. 85.
    Simsir A, Fetsch P, Mehta D, Zakowski M, Abati A. E-cadherin, N-cadherin, and calretinin in pleural effusions: the good, the bad, the worthless. Diagn Cytopathol. 1999;20(3):125–30.PubMedCrossRefGoogle Scholar
  86. 86.
    Mutsaers SE. The mesothelial cell. Int J Biochem Cell Biology. 2004;36(1):9–16.CrossRefGoogle Scholar
  87. 87.
    Chen L, Caldero SG, Gmitro S, Smith ML, De Petris G, Zarka MA. Small orangiophilic squamous-like cells: an underrecognized and useful morphological feature for the diagnosis of malignant mesothelioma in pleural effusion cytology. Cancer Cytopathol. 2014;122(1):70–5.PubMedCrossRefGoogle Scholar
  88. 88.
    Gao L, Reeves W, Demay RM. Parakeratotic-like cells in effusions—a clue to diagnosis of malignant mesothelioma. Cytojournal. 2012;9:18.PubMedPubMedCentralCrossRefGoogle Scholar
  89. 89.
    Kimura N, Dota K, Araya Y, Ishidate T, Ishizaka M. Scoring system for differential diagnosis of malignant mesothelioma and reactive mesothelial cells on cytology specimens. Diagn Cytopathol. 2009;37(12):885–90.PubMedCrossRefGoogle Scholar
  90. 90.
    Cakir E, Demirag F, Aydin M, Unsal E. Cytopathologic differential diagnosis of malignant mesothelioma, adenocarcinoma and reactive mesothelial cells: a logistic regression analysis. Diagn Cytopathol. 2009;37(1):4–10.PubMedCrossRefGoogle Scholar
  91. 91.
    Ordonez NG. Value of immunohistochemistry in distinguishing peritoneal mesothelioma from serous carcinoma of the ovary and peritoneum: a review and update. Adv Anat Pathol. 2006;13(1):16–25.PubMedCrossRefGoogle Scholar
  92. 92.
    Davidson B, Risberg B, Kristensen G, et al. Detection of cancer cells in effusions from patients diagnosed with gynaecological malignancies. Evaluation of five epithelial markers. Virch Arch. 1999;435(1):43–9.CrossRefGoogle Scholar
  93. 93.
    Ordonez NG. Value of estrogen and progesterone receptor immunostaining in distinguishing between peritoneal mesotheliomas and serous carcinomas. Hum Pathol. 2005;36(11):1163–7.PubMedCrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of Pathology, MSPTH 5077University Hospitals Cleveland Medical Center, Case Western Reserve UniversityClevelandUSA

Personalised recommendations